Antihyperlipidemics - Nicotinic Acid and Derivatives

Antihyperlipidemics – Nicotinic Acid and Derivatives constitutes a recognized therapeutic class of lipid-modifying agents that includes nicotinic acid (niacin) and related chemical analogues such as acipimox

Antihyperlipidemics – Nicotinic Acid and Derivatives constitutes a recognized therapeutic class of lipid-modifying agents that includes nicotinic acid (niacin) and related chemical analogues such as acipimox

At pharmacological doses, these agents primarily act by activating hydroxycarboxylic acid receptor 2 (HCA2/GPR109A) in adipose tissue to inhibit lipolysis, thereby decreasing circulating free fatty acid flux to the liver, attenuating hepatic synthesis of very-low-density lipoproteins and triglycerides, and raising high-density lipoprotein cholesterol

At pharmacological doses, these agents primarily act by activating hydroxycarboxylic acid receptor 2 (HCA2/GPR109A) in adipose tissue to inhibit lipolysis, thereby decreasing circulating free fatty acid flux to the liver, attenuating hepatic synthesis of very-low-density lipoproteins and triglycerides, and raising high-density lipoprotein cholesterol

At pharmacological doses, these agents primarily act by activating hydroxycarboxylic acid receptor 2 (HCA2/GPR109A) in adipose tissue to inhibit lipolysis, thereby decreasing circulating free fatty acid flux to the liver, attenuating hepatic synthesis of very-low-density lipoproteins and triglycerides, and raising high-density lipoprotein cholesterol Clinically, this drug class is primarily used as an adjunct to diet in the management of dyslipidemia, mixed dyslipidemia, and severe hypertriglyce...

Clinically, this drug class is primarily used as an adjunct to diet in the management of dyslipidemia, mixed dyslipidemia, and severe hypertriglyceridemia, as well as to lower cardiovascular risk in selected patient populations